Tarsus Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.59%
vs ±10.5% implied · ×0.63
shaded = implied · ▲▼ = realized
Tarsus Pharmaceuticals has 2 disclosed suppliers and 4 disclosed customers in SEC filings.
Tarsus Pharmaceuticals, Inc.
74.85
+0.65 · +0.88%
post 75.94 +1.45%
SentenceIn September 2020, we entered into a license agreement with Elanco granting us a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement").
SentenceThe terms of our Eye and Derm Elanco Agreement, All Human Uses Elanco Agreement, Other In-License Agreement, and February 2026 In-License Agreement require us to make future development milestone payments aggregating up to $11.5 million and future commercial and sales-based milestone payments aggregating up to $341.0 million upon our achievement of the specified milestones.
TARS 10-Kaccession 0001819790-26-000019
SentenceIn March 2024, we executed the Novation Agreement with GrandPharma and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of Demodex blepharitis and MGD.
TARS 10-Kaccession 0001819790-26-000019
In March 2024, we executed the Novation Agreement with GrandPharma and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of Demodex blepharitis and MGD.
TARS 10-Kaccession 0001819790-26-000019
SentenceThrough December 31, 2025, we received aggregate payments from LianBio totaling $86.1 million comprised of: (i) $15.0 million of initial consideration; (ii) $67.5 million for the achievement of specified milestones; (iii) $2.5 million upon execution of the Novation Agreement; (iv) $0.4 million upon execution of the Warrant Termination Agreement; and (v) $0.7 million related to a special cash dividend.
TARS 10-Kaccession 0001819790-26-000019
SentenceAs of December 31, 2025, we are eligible to receive further consideration from GrandPharma upon the achievement of additional TP-03 events, including: (i) additional regulatory and/or patent issuance milestones of up to an aggregate of $20.0 million; (ii) China-based TP-03 sales threshold milestone payments of up to an aggregate of $100.0 million and (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales.
TARS 10-Kaccession 0001819790-26-000019
Expected move
Inputs8Q avg ±6.4%·×2.01·rich
straddle ±14.7%
spot 74.85exp Nov 20ATM strike 75ATM straddle 12.95IV 91%